PRESS RELEASE published on 05/27/2024 at 07:00, 1 year 9 months ago Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation La FDA accorde l'examen prioritaire au Sarclisa pour le traitement du myélome multiple nouvellement diagnostiqué non éligibles à une transplantation. Sanofi annonce des résultats positifs de l'étude IMROZ FDA Sanofi Myélome Multiple Sarclisa Examen Prioritaire
BRIEF published on 05/21/2024 at 07:35, 1 year 10 months ago Sanofi, Formation Bio, and OpenAI Announce AI Collaboration Collaboration AI Drug Development Sanofi OpenAI Formation Bio
BRIEF published on 05/21/2024 at 07:35, 1 year 10 months ago Sanofi, Formation Bio et OpenAI annoncent une collaboration en matière d'IA Collaboration Développement De Médicaments IA Sanofi OpenAI Biographie De La Formation
PRESS RELEASE published on 05/21/2024 at 07:30, 1 year 10 months ago Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Sanofi, Formation Bio, and OpenAI collaborate to accelerate drug development with AI-powered software. The partnership aims to bring new medicines more efficiently Collaboration Drug Development Sanofi OpenAI Formation Bio
PRESS RELEASE published on 05/21/2024 at 07:30, 1 year 10 months ago Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Sanofi, Formation Bio et OpenAI annoncent une coopération pour développer des logiciels alimentés par l'IA afin d'accélérer le développement de médicaments. Première collaboration de ce genre dans les industries pharmaceutiques et des sciences de la vie IA Sanofi Développement De Médicaments OpenAI Formation Bio
BRIEF published on 05/20/2024 at 22:59, 1 year 10 months ago Sanofi: April 2024 Voting Rights and Shares Information Voting Rights Shares Financial Disclosure April 2024 Sanofi
BRIEF published on 05/20/2024 at 22:59, 1 year 10 months ago Sanofi : Informations sur les droits de vote et les actions d'avril 2024 Actions Droit De Vote Divulgation Financière Avril 2024 Sanofi
PRESS RELEASE published on 05/20/2024 at 22:54, 1 year 10 months ago Sanofi: Information concerning the total number of voting rights and shares - April 2024 Sanofi provides total number of issued shares and voting rights as per French Commercial Code and AMF regulations for April 30, 2024 Share Capital Voting Rights French Commercial Code AMF Regulations Sanofi
PRESS RELEASE published on 05/20/2024 at 22:54, 1 year 10 months ago Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024 Annonce du nombre total de droits de vote et d'actions de Sanofi selon les réglementations en vigueur. Informations disponibles sur le site internet de l'entreprise Autorité Des Marchés Financiers Droits De Vote Actions Relations Investisseurs Sanofi
BRIEF published on 05/20/2024 at 20:20, 1 year 10 months ago Dupixent® réduit les exacerbations de la BPCO selon une étude de phase III FDA Étude Clinique Inflammation BPCO Dupixent
Published on 03/20/2026 at 13:30, 2 days 7 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 8 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 8 hours 31 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 22 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 23 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 23 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 2 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 2 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA